Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Niels-Henrik Jensen"'
Publikováno v:
Højsted, J, Handberg, G, Jensen, N-H & Staehelin Jensen, T 2019, Organisation af smerteområdet . i M U Werner, N B Finnerup & L Arendt-Nielsen (red), Smerter-baggrund, evidens og behandling . 4 udg, FADL's Forlag, København, s. 716-726 .
Aarhus University
Aarhus University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a5433fc3bfc3ea96c99de4475cdbd910
https://pure.au.dk/portal/da/publications/organisation-af-smerteomraadet(742235d4-731f-4655-82f5-5aea9d4c9a4a).html
https://pure.au.dk/portal/da/publications/organisation-af-smerteomraadet(742235d4-731f-4655-82f5-5aea9d4c9a4a).html
Autor:
S. Kendall, Per Sjøgren, Jette Højsted, Niels-Henrik Jensen, P. H. Rotbøll Nielsen, L. Frich, N. R. Holm
Publikováno v:
Acta Anaesthesiologica Scandinavica. 57:920-928
Background There is currently no instrument to systematically assess the range of symptoms/problems and their bothersomeness in patients with chronic non-cancer pain (CNPN). Systematic assessment and prioritizing may target treatments and improve out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::711e4467a319618c31c0e7e9d46234ca
https://doi.org/10.1111/aas.12137
https://doi.org/10.1111/aas.12137
Autor:
Pirkko Paakkari, Eija Kalso, Niels Henrik Jensen, Harald Breivik, Katri Hamunen, Pirjo Laitinen-Parkkonen, Torsten Gordh
Publikováno v:
European Journal of Pain. 12:705-715
Objective The objective of this paper was to analyse opioid consumption in a number European countries using different sources of data. Methods Data were extracted from the United Nations’ International Narcotics Control Board Report (INCB) 2003 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4f18ed1cacb52ffdec379cba74cfe6
https://doi.org/10.1016/j.ejpain.2007.10.012
https://doi.org/10.1016/j.ejpain.2007.10.012
Autor:
Kim Kristensen, Ulrik Skram, Steen Honoré Hansen, Lona L. Christrup, Niels-Henrik Jensen, Hanne H. Villesen
Publikováno v:
European Journal of Clinical Pharmacology. 63:761-767
After oral administration, morphine-6-glucuronide (M6G) displays an atypical absorption profile with two peak plasma concentrations. A proposed explanation is that M6G is hydrolysed to morphine in the colon, which is then absorbed and subsequently un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43be4667c2f373b11478ead4064dbd9
https://doi.org/10.1007/s00228-007-0306-4
https://doi.org/10.1007/s00228-007-0306-4
Autor:
Mette Rasmussen, Birte Hedal, Hanne H. Villesen, Sven Frokjaer, Niels-Henrik Jensen, Ulrik Skram, Lene Stevner, Jens Engbaek, Steen Honoré Hansen, Lona L. Christrup
Publikováno v:
Acute Pain. 8:63-71
Summary Background The active metabolite of morphine, morphine-6-glucuronide (M6G), shows an analgesic effect that is equivalent to morphine. The bioavailability is low (11–13%) when given orally due to poor absorption from the GI-tract and further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::067aa62fed05bf8cbfb475d59a4cf93d
https://doi.org/10.1016/j.acpain.2006.04.001
https://doi.org/10.1016/j.acpain.2006.04.001
Publikováno v:
American Journal of Drug Delivery. 2:75-88
Chewing gum has been used for centuries to clean the mouth or freshen the breath. The first patent on chewing gum was filed in 1869 and the first medicated chewing gum was commercially introduced in 1928. In 1991, The European Pharmacopoeia defined t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f097edc9d6aa5357792cbb22e7a54e
https://doi.org/10.2165/00137696-200402020-00001
https://doi.org/10.2165/00137696-200402020-00001
Publikováno v:
Journal of Pain & Palliative Care Pharmacotherapy. 17:5-26
A Markov model was constructed to simulate the resource use and health outcomes of one year of treatment comparing the fentanyl transdermal therapeutic system (fentanyl-TTS) with oral sustained-release (SR) morphine in outpatients with noncancer pain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5510b6d42999590ff94482a8e03960f3
https://doi.org/10.1080/j354v17n02_02
https://doi.org/10.1080/j354v17n02_02
Publikováno v:
Palliative Medicine. 16:107-114
Background: Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2062f469e6450365f06349296277d2c5
https://doi.org/10.1191/0269216302pm512oa
https://doi.org/10.1191/0269216302pm512oa
Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long-Term Morphine Treatment
Publikováno v:
Journal of Pain and Symptom Management. 23:161-164
A cancer patient receiving long-term oral sustained-release morphine treatment and periodically presenting with unusually high plasma M3G/M6G ratios is described. We found the patient's formation of M6G more unstable and perhaps delayed compared to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3879d53c9ea6fd33af9862fbc449e700
https://doi.org/10.1016/s0885-3924(01)00398-0
https://doi.org/10.1016/s0885-3924(01)00398-0
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 5:20-24
This study describes self-reported functional and psychological status of patients using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and relates this to the prognosis. Patients with incurable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4bed96ed0060d1092268f7c27016a0a
https://doi.org/10.1016/s1078-1439(98)00039-8
https://doi.org/10.1016/s1078-1439(98)00039-8